Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Legend Biotech Corporation or Zymeworks Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Legend Biotech Corporation and Zymeworks Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Legend Biotech Corporation and Zymeworks Inc.

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Latest Biotechnology and Legend Biotech Corporation, Zymeworks Inc. Stock News

As of December 19, 2025, Legend Biotech Corporation had a $4.0 billion market capitalization, compared to the Biotechnology median of $206.2 million. Legend Biotech Corporation’s stock is down 30.3% in 2025, up 3.1% in the previous five trading days and down 36.79% in the past year.

Currently, Legend Biotech Corporation does not have a price-earnings ratio. Legend Biotech Corporation’s trailing 12-month revenue is $909.0 million with a -26.4% net profit margin. Year-over-year quarterly sales growth most recently was 70.0%. There are no analysts providing consensus earnings estimates for the current fiscal year. Legend Biotech Corporation does not currently pay a dividend.

As of December 19, 2025, Zymeworks Inc. had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. Zymeworks Inc.’s stock is up 88.7% in 2025, up 6.4% in the previous five trading days and up 103.67% in the past year.

Currently, Zymeworks Inc. does not have a price-earnings ratio. Zymeworks Inc.’s trailing 12-month revenue is $134.5 million with a -47.2% net profit margin. Year-over-year quarterly sales growth most recently was 72.5%. Analysts expect adjusted earnings to reach $-0.873 per share for the current fiscal year. Zymeworks Inc. does not currently pay a dividend.

How We Compare Legend Biotech Corporation and Zymeworks Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Legend Biotech Corporation and Zymeworks Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Legend Biotech Corporation and Zymeworks Inc. Growth Grades

Company	Ticker	Growth
Legend Biotech Corporation	LEGN	F
Zymeworks Inc.	ZYME	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Legend Biotech Corporation has a Growth Score of 20, which is Very Weak. Zymeworks Inc. has a Growth Score of 13, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Legend Biotech Corporation or Zymeworks Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Legend Biotech Corporation or Zymeworks Inc. is the better investment when it comes to sustainable growth.

Legend Biotech Corporation and Zymeworks Inc.’s Quality Grades

Company	Ticker	Quality
Legend Biotech Corporation	LEGN	D
Zymeworks Inc.	ZYME	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Legend Biotech Corporation has a Quality Score of 30, which is Weak. Zymeworks Inc. has a Quality Score of 35, which is Weak.

The Quality Stock Winner: No Clear Winner

Neither Legend Biotech Corporation or Zymeworks Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Legend Biotech Corporation or Zymeworks Inc. is the better investment when it comes to quality.

Legend Biotech Corporation and Zymeworks Inc.’s Momentum Grades

Company	Ticker	Momentum
Legend Biotech Corporation	LEGN	F
Zymeworks Inc.	ZYME	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Legend Biotech Corporation has a Momentum Score of 12, which is Very Weak. Zymeworks Inc. has a Momentum Score of 94, which is Very Strong.

The Momentum Grade Winner: Zymeworks Inc.

As you can clearly see from the Momentum Grade breakdown above, Zymeworks Inc. is considered to have stronger momentum compared to Legend Biotech Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Zymeworks Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Legend Biotech Corporation and Zymeworks Inc. Grades

In addition to Momentum, Quality and Growth, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Legend Biotech Corporation and Zymeworks Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Legend Biotech Corporation or Zymeworks Inc. Stock?

Overall, Legend Biotech Corporation stock has a Growth Score of 20, Momentum Score of 12 and Quality Score of 30.

Zymeworks Inc. stock has a Growth Score of 13, Momentum Score of 94 and Quality Score of 35.

Comparing Legend Biotech Corporation and Zymeworks Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.